European Commission Clears Label Extension for Roche’s Evrysdi
Treatment indicated for babies under two months old with spinal muscular atrophy.
In a company press release, Roche revealed that the European Commission (EC) has approved the extension of Evrysdi for infants with a clinical diagnosis of spinal muscular atrophy (SMA) from birth to below two months of age. The approval comes amid positive data from the ongoing rainbowfish trial in pre-symptomatic babies from birth to six weeks with type 1 SMA.
“With this label extension, we can treat babies soon after birth with Evrysdi, allowing them the greatest chance to achieve the milestones of sitting, standing, and walking, similar to healthy children,” said Levi Garraway, MD, PhD., chief medical officer, head of global product development, Roche, in the company release.
Reference: European Commission approves Roche’s Evrysdi for babies under two months old with spinal muscular atrophy (SMA). Roche. August 29, 2023. Accessed August 29, 2023. https://www.roche.com/media/releases/med-cor-2023-08-29
The Misinformation Maze: Navigating Public Health in the Digital Age
March 11th 2025Jennifer Butler, chief commercial officer of Pleio, discusses misinformation's threat to public health, where patients are turning for trustworthy health information, the industry's pivot to peer-to-patient strategies to educate patients, and more.
Navigating Distrust: Pharma in the Age of Social Media
February 18th 2025Ian Baer, Founder and CEO of Sooth, discusses how the growing distrust in social media will impact industry marketing strategies and the relationships between pharmaceutical companies and the patients they aim to serve. He also explains dark social, how to combat misinformation, closing the trust gap, and more.
